NASDAQ:CRME - Cardiome Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$2.38
Today's Range$2.30 - $2.45
52-Week Range$1.29 - $4.84
Volume90,444 shs
Average Volume135,322 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Receive CRME News and Ratings via Email

Sign-up to receive the latest news and ratings for CRME and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRME
Previous Symbol
CUSIPN/A
Phone604-677-6905

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees120
Outstanding SharesN/A
Market Cap$0.00
OptionableOptionable

Cardiome Pharma (NASDAQ:CRME) Frequently Asked Questions

What is Cardiome Pharma's stock symbol?

Cardiome Pharma trades on the NASDAQ under the ticker symbol "CRME."

How were Cardiome Pharma's earnings last quarter?

Cardiome Pharma Co. (NASDAQ:CRME) issued its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.02. The biopharmaceutical company had revenue of $6.54 million for the quarter, compared to the consensus estimate of $7.34 million. View Cardiome Pharma's Earnings History.

What price target have analysts set for CRME?

3 analysts have issued 12 month target prices for Cardiome Pharma's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Cardiome Pharma's share price to reach $7.50 in the next year. View Analyst Price Targets for Cardiome Pharma.

What is the consensus analysts' recommendation for Cardiome Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiome Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardiome Pharma.

Has Cardiome Pharma been receiving favorable news coverage?

Headlines about CRME stock have been trending very positive on Monday, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cardiome Pharma earned a coverage optimism score of 3.9 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.

Who are some of Cardiome Pharma's key competitors?

Who are Cardiome Pharma's key executives?

Cardiome Pharma's management team includes the folowing people:
  • Dr. William L. Hunter, Pres, CEO & Director (Age 55)
  • Ms. Sheila M. Grant MBA, Chief Operating Officer
  • Mr. David D. McMasters, Gen. Counsel (Age 59)
  • Mr. Hugues Sachot, Chief Commercial Officer
  • Mr. Justin A. Renz, Chief Financial Officer (Age 46)

How do I buy shares of Cardiome Pharma?

Shares of CRME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cardiome Pharma's official website?

The official website for Cardiome Pharma is http://www.cardiome.com.

How can I contact Cardiome Pharma?

Cardiome Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The biopharmaceutical company can be reached via phone at 604-677-6905 or via email at [email protected]


MarketBeat Community Rating for Cardiome Pharma (NASDAQ CRME)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  447
MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma and other stocks. Vote "Outperform" if you believe CRME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRME will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by MarketBeat.com Staff

Featured Article: Consumer Price Index (CPI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel